Press releases

New operating structure designed to increase efficiency and support continued growth MARLBOROUGH, Mass., Oct. 7, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the...

Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 21st Annual Healthcare Conference on Thursday, September 10, 2026. Mike Mahoney, chairman and chief executive officer,...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational1 and...

Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease

Accelerated share repurchase agreement is part of Company's previously announced $5 billion share repurchase authorization.

Agreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloy.

A live webcast and replay of both events will be available. Learn how to tune in.

Positive data for FARAPULSE™ Pulsed Field Ablation and WATCHMAN™ LAAC Devices underscore therapy safety and effectiveness in late-breaking clinical trial sessions

"Our global team and the strength of our category leadership strategy enabled us to deliver solid results this quarter," said Mike Mahoney, chairman and chief executive officer.

A webcast and replay of the April 22 conference call will be available. Learn how to tune in.

New technology designed to provide a single irrigation management system for ureteroscopy, cystoscopy, percutaneous nephrolithotomy (PCNL) and benign prostatic hyperplasia (BPH) procedures.

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrillation.

Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs anticoagulation alone.

The American College of Cardiology investor event on March 28 will feature a live webcast. Learn how to tune in or access the replay.

"Each brings deep leadership experience, strategic insight and a strong track record of value creation,” said CEO Mike Mahoney.

Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 46th Annual Health Care Conference on Tuesday, March 3, 2026. Mike Mahoney, chairman and chief executive officer, and...

“2025 was another exceptional year for Boston Scientific,” said Mike Mahoney, chairman and CEO.

Three clinical studies reinforce the sustained impact and efficacy of spinal cord stimulation (SCS) for treating chronic pain

Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and...

Acquisition to expand urology offerings for people living with overactive bladder MARLBOROUGH, Mass., Jan. 12, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has...

A live webcast and replay will be available for the January 13 conference session and the February 4 conference call

Webcasts of the November 18 and December 25 investor conference sessions will be available. Learn how to tune in live or watch the replays.

"We delivered a quarter marked by exceptional performance,” said Mike Mahoney, chairman and CEO.

Acquisition to expand the neuromodulation offerings for people living with chronic pain

Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Tuesday, September 30, 2025.